Floatz logo

Sgm-101

Rectal Cancer

Leiden University Medical CenterPhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

114 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

Sgm-101 is also rated in:

rectal cancerDormant
BB
Indicative ·
64 / 100
View asset →
colorectal neoplasmDormant
B
Indicative ·
59 / 100
View asset →
metastasis from malignant tumor of colonDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →